Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.

The disclosure is directed to compositions comprising a prodrug and an immunomodulator, which can self-assemble into a nanofiber hydrogel at the site of application in a human. The prodrug comprises one or more cytotoxic agents conjugated to a hydrophilic moiety by a linker. The compositions may be used to kill cancer cells, such as glioblastoma and colorectal cancer cells.

The disclosure is directed to compositions comprising a prodrug and an immunomodulator, which can self-assemble into a nanofiber hydrogel at the site of application in a human. The prodrug comprises one or more cytotoxic agents conjugated to a hydrophilic moiety by a linker. The compositions may be used to kill cancer cells, such as glioblastoma and colorectal cancer cells.

A compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof;

##STR00001##

in which X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, Y, and are as described in the claims, for the use thereof in the treatment of bacterial infections including those caused by caused by at least one bacterium of the genus selected from aerobic Gram-positive bacteria; Gram-negative enterobacteria; Gram-negative bacilli; Gram-negative anaerobic bacteria; Gram-positive anaerobic bacteria; mycobacteria and pathogens involved in sexually transmitted infections.

A compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof;

##STR00001##

in which X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, Y, and are as described in the claims, for the use thereof in the treatment of bacterial infections including those caused by caused by at least one bacterium of the genus selected from aerobic Gram-positive bacteria; Gram-negative enterobacteria; Gram-negative bacilli; Gram-negative anaerobic bacteria; Gram-positive anaerobic bacteria; mycobacteria and pathogens involved in sexually transmitted infections.

A composition for treating and/or preventing Hepatitis B virus infection and Hepatitis B virus infection mediated diseases and the method thereof are provided. In some embodiments, the composition includes a polyriboinosinic acid-polyribocytidylic acid (PIC), at least one antibiotic or polyamide compound, at least one positive ion, and Hepatitis B virus surface antigen. In some embodiments, the composition includes PIC, at least one antibiotic or polyamide compound, at least one positive ion, Hepatitis B virus surface antigen and Hepatitis B virus core antigen. The present disclosure also relates to a method of treating and/or preventing Hepatitis B virus infection, particularly for treating chronic HBV infection.

A composition for treating and/or preventing Hepatitis B virus infection and Hepatitis B virus infection mediated diseases and the method thereof are provided. In some embodiments, the composition includes a polyriboinosinic acid-polyribocytidylic acid (PIC), at least one antibiotic or polyamide compound, at least one positive ion, and Hepatitis B virus surface antigen. In some embodiments, the composition includes PIC, at least one antibiotic or polyamide compound, at least one positive ion, Hepatitis B virus surface antigen and Hepatitis B virus core antigen. The present disclosure also relates to a method of treating and/or preventing Hepatitis B virus infection, particularly for treating chronic HBV infection.

The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34λ.sup.5,39λ.sup.5-diphosphaoctacyclo[28.6.4.1.sup.3,36.1.sup.28,31.0.sup.4,8.0.sup.7,12.0.sup.19,24.0.sup.23,27]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals. ##STR00001##

The present invention relates to a virus-like particle for preventing or treating toxoplasmosis, comprising influenza virus matrix protein 1; and surface antigen proteins comprising an inner membrane complex, Rhoptry protein 18 and Microneme protein 8 derived from Toxoplasma gondii, and a pharmaceutical composition comprising the same.

The present invention relates to a virus-like particle for preventing or treating toxoplasmosis, comprising influenza virus matrix protein 1; and surface antigen proteins comprising an inner membrane complex, Rhoptry protein 18 and Microneme protein 8 derived from Toxoplasma gondii, and a pharmaceutical composition comprising the same.